Radiotherapy Support Nutrition Market Projected to Reach USD 594.3 Million by 2036

Sales of nutrition products designed to support patients undergoing radiotherapy are projected to increase from USD 239.8 million in 2025 to USD 260.4 million in 2026. This growth is largely driven by the challenges some cancer patients face when eating normally due to treatment, particularly those undergoing radiation therapy to the head, neck, chest, or gastrointestinal tract. Common issues such as difficulty swallowing, reduced appetite, altered taste, and gastrointestinal discomfort necessitate specialized nutritional support that may begin with concentrated oral formulations and evolve to texture-modified or enteral feeding solutions.

This specific market represents an essential segment within the broader clinical nutrition industry. Patients often start with high-protein oral nutrition supplements (ONS) and may require smoother products as swallowing becomes painful. Eventually, if oral intake diminishes sufficiently, they may need enteral feeding. Therefore, establishing a consistent product availability tailored to patient needs throughout their treatment journey is crucial, though factors like reimbursement policies and patient tolerance can affect ongoing product usage.

Key insights from market analysis include:

- Radiotherapy-induced challenges such as swallowing difficulties and appetite loss create sustained demand for concentrated nutritional support.

- High-Protein ONS is forecasted to dominate the product type category with a 40.6% market share in 2026, as it effectively supplements calorie intake when patients can still consume orally.

- The head and neck area is anticipated to account for 41.7% of demand based on treatment impact on eating abilities.

- Regional growth forecasts show South Korea leading with an 8.7% CAGR, followed by the USA at 8.1% among the countries analyzed.

Major players in the radiotherapy support nutrition market include Nestlé Health Science, Danone Nutricia, Abbott, Fresenius Kabi, Medtrition, Victus, B. Braun, and Lyons Health Labs.

According to Anurag Sharma, Principal Consultant at Future Market Insights, the market thrives best when suppliers adapt their offerings in alignment with changing patient needs throughout the treatment process. A static high-protein product won’t suffice on its own; rather, suppliers must ensure a seamless transition to products that meet evolving dietary requirements during and after cancer therapy.